ArticleProstate cancer and prostatic diseases2020
Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities.
Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Trial
- Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.Japanese journal of clinical oncology · 2022Trial
- A hospital-based study of prostate biopsy results in Indian males.Journal of family medicine and primary care · 2024Article
- Causality investigation among gut microbiota, immune cells, and prostate diseases: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Mechanisms of action ofFrontiers in pharmacology · 2024Article
- Impact of fast-track surgery-oriented care pathways on perioperative rehabilitation indices in patients undergoing radical prostatectomy for prostate cancer.American journal of translational research · 2024Article
- 'Is it painful'? A qualitative study on experiences of patients before prostate needle biopsy.BMJ open · 2022Article
- Long non‑coding RNA CASC11 interacts with YBX1 to promote prostate cancer progression by suppressing the p53 pathway.International journal of oncology · 2022Article
- Effect of taurine on the proliferation, apoptosis andTranslational cancer research · 2022Article
- Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer.Investigative and clinical urology · 2022Article
- Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups.JCO oncology practice · 2022Article
- Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach.Korean journal of radiology · 2021Review
- Prospective Study of the Clinical Impact of Epithelial and Mesenchymal Circulating Tumor Cells in Localized Prostate Cancer.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31811242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.